Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Arrakis Therapeutics
Biotech
BMS, Merck KGa in protein degradation race with Amphista pacts
Bristol Myers Squibb and Merck KGaA have made further moves in the protein degrader space, inking deals with British biotech Amphista Therapeutics.
Max Bayer
May 4, 2022 8:00am
Amgen teams up with Arrakis in $75M RNA-destroying research deal
Jan 11, 2022 9:00am
'Leadership is showing': Biotech execs detail being openly LGBTQ
Dec 7, 2021 7:00am
Advent raises $215M to nurture another troop of biotechs
Feb 18, 2021 2:00am
Arrakis, Roche team up on RNA-targeting drugs in $190M deal
Apr 8, 2020 6:00am
Gilman buckles in as Arrakis raises $75M—Chutes & Ladders
Apr 19, 2019 9:30am
